Landos Biopharma (Landos Biopharma) EBIT : $-25.54 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Landos Biopharma EBIT?

Landos Biopharma's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-9.30 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-25.54 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Landos Biopharma's annualized ROC % for the quarter that ended in Mar. 2024 was %. Landos Biopharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Landos Biopharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -60.45%.

Landos Biopharma EBIT Historical Data

The historical data trend for Landos Biopharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Landos Biopharma EBIT Chart

Landos Biopharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-13.16

-30.68

-38.82

-40.56

-22.73

Landos Biopharma Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-6.48	-4.44	-5.20	-6.61	-9.30

Competitive Comparison of Landos Biopharma's EBIT

For the Biotechnology subindustry, Landos Biopharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Landos Biopharma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Landos Biopharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Landos Biopharma's EV-to-EBIT falls into.

Landos Biopharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.54 Mil.

Landos Biopharma (NAS:LABP) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Landos Biopharma's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-37.18 * ( 1 - 0% )	/	( (0	+	0)	/ 2 )
=	-37.18	/	0
=	%

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	38.04	-	6.249	-	( 37.499	-	max(0, 6.249	-	38.04	+	37.499	))
=	0

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	29.896	-	6.742	-	( 29.004	-	max(0, 6.742	-	29.896	+	29.004	))
=	0

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Landos Biopharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-37.18	/	( ( (0 + max(-5.708, 0))	+	(0 + max(-5.85, 0)) )	/	2 )
=	-37.18	/	( ( 0	+	0 )	/	2 )
=	-37.18	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.541)	-	(6.249	+	0	+	0)
=	-5.708

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.892)	-	(6.742	+	0	+	0)
=	-5.85

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Landos Biopharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-25.543	/	42.256
	=	-60.45 %

Landos Biopharma EBIT Related Terms

Thank you for viewing the detailed overview of Landos Biopharma's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Landos Biopharma (Landos Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Landos Biopharma Inc (NAS:LABP) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 11239, Blacksburg, VA, USA, 24060

Website

https://www.landosbiopharma.com

Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. It has several active development programs, each discovered internally, targeting novel pathways at the interface of immunity and metabolism. It operates in one reportable segment of operations and manages.

Executives

Alka Batycky	director	C/O LANDOS BIOPHARMA, INC., P.O. BOX 11239, BLACKSBURG VA 24062
Perceptive Xontogeny Venture Fund Ii, Lp	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Roderick Wong	10 percent owner	C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Fabio Cataldi	officer: Chief Medical Officer	C/O LANDOS BIOPHARMA, INC., PO BOX 11239, BLACKSBURG VA 24062
Gregory Oakes	director, officer: Chief Executive Officer	760 PARKSIDE AVENUE, SUITE 304, BROOKLYN NY 11226
Patrick Truesdell	officer: Vice President and Controller	C/O LANDOS BIOPHARMA, INC., 1800 KRAFT DRIVE, SUITE 216, BLACKBURG VA 24060
Roger Adsett	director	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Josep Bassaganya-riera	director, 10 percent owner, officer: Chairman, President and CEO	1800 KRAFT DRIVE, SUITE 100, BLACKSBURG VA 24060
Patricia L Bitar	officer: Interim CFO	C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, STE 700, SAN DIEGO CA 92122
Perceptive Xontogeny Venture Fund, Lp	director	C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Xontogeny, Llc	director	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Fred Callori	director	100 HIGH STREET, 28TH FLOOR, BOSTON MA 02110
Joseph Edelman	director	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd	director	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003